ID   FHs 738Bl
AC   CVCL_T279
DR   ATCC; HTB-160
DR   IARC_TP53; 3718
DR   Wikidata; Q54834898
RX   PubMed=7787250;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.226_278del53; Zygosity=Unspecified (PubMed=7787250).
CC   Discontinued: ATCC; HTB-160; true.
CC   Derived from site: In situ; Fetal urinary bladder; UBERON=UBERON_0001255.
CC   Cell type: Fibroblast; CL=CL_0000057.
ST   Source(s): ATCC=HTB-160
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,11
ST   D16S539: 9,11
ST   D5S818: 11,13
ST   D7S820: 8,12
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 16,18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_3309 ! FHs 738Lu
OI   CVCL_R767 ! Hs 738.Bl
OI   CVCL_S035 ! Hs 738.Eye
OI   CVCL_S314 ! Hs 738.K/Ad/Ts
OI   CVCL_0879 ! Hs 738.Lu
OI   CVCL_0880 ! Hs 738.St/Int
SX   Male
AG   18FW
CA   Finite cell line
DT   Created: 03-02-14; Last updated: 02-05-24; Version: 9
//
RX   PubMed=7787250;
RA   Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J.,
RA   Lippa M., Hatzivassiliou G., Tan J.;
RT   "p53 mutations in bladder carcinoma cell lines.";
RL   Oncol. Res. 6:569-579(1994).
//